In the high-stakes world of large-cap investing, a Piotroski Score of 9 is the ultimate “clean bill of health.” It means a company has cleared all nine criteria involving profitability, liquidity, and operating efficiency.
As of April 4, 2026, only two Indian large-caps have achieved this perfect score—both from the pharmaceutical sector. This comes at a time when the Indian pharma market is projected to more than double, reaching $130 billion by 2030.
What is the Piotroski Score?
The score, developed by Joseph Piotroski, evaluates a company on a scale of 0 to 9. A score of 9 indicates exceptionally strong upward momentum in financial health.
1. Sun Pharmaceutical Industries Ltd. (The Global Giant)
Sun Pharma is the undisputed leader in the Indian pharmaceutical space, with a market cap exceeding ₹4 lakh crore.
-
Financial Strength: Logged a 10.7% YoY revenue growth in 9MFY26 (reaching ₹43,850 crore).
-
The “Specialty” Pivot: The 2025 acquisition of Checkpoint Therapeutics gave Sun Pharma the first-ever FDA-approved Anti-PD-L1 antibody for skin cancer, significantly boosting its oncology profile.
-
Efficiency: Despite its massive size, it maintains a ROCE of 20.2% (vs. the industry median of 15.1%) and a nearly negligible debt-to-equity ratio of 0.07.
Revenue Breakdown (Q3FY26)
| Segment | Contribution | YoY Growth |
| India Formulations | 32% | +16.2% |
| US Formulations | 28% | +6.2% |
| Emerging Markets | 19% | +28.3% |
| Rest of World | 17% | +20.8% |
2. Torrent Pharmaceuticals Ltd. (The Branded Generic Leader)
Torrent Pharma ranks as the 3rd largest pharma business in India (Market Cap: ₹1.35 lakh crore), focusing heavily on high-margin chronic therapies.
-
Strategic Growth: In January 2026, Torrent secured a controlling 48.8% stake in JB Pharma, a move expected to save up to ₹450 crore in costs over two years through manufacturing and R&D synergies.
-
Profitability Surge: Net profit jumped 25.5% YoY to ₹1,774 crore in 9MFY26.
-
Return on Capital: It boasts a stellar ROCE of 27.1%, outperforming even Sun Pharma.
-
Global Footprint: While India is its largest market, it has 60 new molecules currently awaiting regulatory approval in Brazil.
The Valuation Reality Check
While their financials are perfect, their stock prices are not “cheap.” Both companies trade at a significant premium compared to their peers, reflecting the market’s high confidence in their stability.
| Metric | Sun Pharma | Torrent Pharma | Industry Median |
| Piotroski Score | 9 | 9 | ~5-6 |
| P/E Ratio | 33.5x | 58.5x | 27.1x |
| PEG Ratio | 1.7x | 2.8x | 0.8x |
| Debt-to-Equity | 0.07 | 0.33 | 0.22 |
Summary for Investors
The perfect scores for Sun and Torrent Pharma suggest they are well-insulated against the current market volatility caused by geopolitical tensions in the Middle East. However, with PEG ratios well above 1.0, investors are paying a high “quality premium” for these shares.
